文献速递肿瘤 PET/CT

使用64Cu-DOTA-曲妥珠单抗PET预测接受曲妥珠单抗美坦新辅助治疗转移性乳腺癌患者的缓解与结局:一项先导研究

Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study.
PubMed 文献 · J Nucl Med · 2021-12-02

十例HER2阳性转移性乳腺癌女性在T-DM1治疗前接受18F-FDG PET/CT及64Cu-DOTA-曲妥珠单抗PET/CT(第1天和第2天)。T-DM1缓解患者的64Cu-DOTA-曲妥珠单抗摄取高于未缓解患者,第2天最小SUVmax高于阈值的患者中位至治疗失败时间显著长于低于阈值者。结论认为该PET/CT测量曲妥珠单抗肿瘤摄取有望识别可从T-DM1获益的转移性乳腺癌患者。

要点

  • T-DM1缓解患者第1天最小SUVmax为5.6,未缓解患者为2.8(P < 0.02)。
  • 第2天最小SUVmax高于阈值者中位至治疗失败时间为28个月,低于阈值者为2个月(P < 0.02)。
  • 64Cu-DOTA-曲妥珠单抗PET/CT有望识别可从T-DM1获益的转移性乳腺癌患者。

核心结论

  • 通过PET/CT测量肿瘤内曲妥珠单抗摄取有望识别可从T-DM1获益的转移性乳腺癌患者。

研究设计与样本

  • 先导研究,纳入10例接受T-DM1治疗的HER2阳性转移性乳腺癌女性。
  • 在T-DM1治疗前第1天和第2天行18F-FDG PET/CT和64Cu-DOTA-曲妥珠单抗PET/CT。

主要发现

  • T-DM1缓解患者64Cu-DOTA-曲妥珠单抗摄取高于未缓解患者:第1天最小SUVmax 5.6 vs 2.8(P < 0.02)。
  • 第2天最小SUVmax缓解患者8.1 vs 未缓解患者3.2(P < 0.01)。
  • 第2天平均SUVmax缓解患者8.5 vs 未缓解患者5.4(P < 0.05)。
  • 肿瘤水平缓解提示对SUVmax的阈值依赖性:第2天最小SUVmax高于阈值者中位至治疗失败时间28个月 vs 低于阈值者2个月(P < 0.02)。

临床怎么用

  • 原文结论认为通过PET/CT测量肿瘤内曲妥珠单抗摄取有望识别可从T-DM1获益的转移性乳腺癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We hypothesized that functional imaging with 64Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody-drug conjugate trastuzumab-emtansine (T-DM1). Methods: Ten women with metastatic human epidermal growth factor receptor 2-positive breast cancer underwent 18F-FDG PET/CT and 64Cu-DOTA-trastuzumab PET/CT on days 1 and 2 before treatment with T-DM1. Results: T-DM1-responsive patients had higher uptake than nonresponsive patients. Day 1 minimum SUVmax (5.6 vs. 2.8, P < 0.02), day 2 minimum SUVmax (8.1 vs. 3.2, P < 0.01), and day 2 average SUVmax (8.5 vs. 5.4, P < 0.05) for 64Cu-DOTA-trastuzumab all favored responding patients. Tumor-level response suggested threshold dependence on SUVmax Patients with a day 2 minimum SUVmax above versus below the threshold had a median time to treatment failure of 28 mo versus 2 mo (P < 0.02). Conclusion: Measurement of trastuzumab uptake in tumors via PET/CT is promising for identifying patients with metastatic breast cancer who will benefit from T-DM1.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mortimer JE, Bading JR, Frankel PH, et al. Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study. J Nucl Med. 2021. PMID: 34857660. doi:10.2967/jnumed.121.262940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。